|
**Overview**: FISH Opposite Sex BMT Panel**Introduction**: The FISH Opposite Sex BMT Panel is a diagnostic tool designed to monitor opposite-sex bone marrow transplantation using whole blood samples. In India, allogeneic HSCT from opposite-sex donors is common in thalassemia, leukemia, and aplastic anemia (~5,000-10,000 transplants/year), with XX/XY chimerism analysis essential for engraftment monitoring and relapse detection. High morbidity from under-monitoring in rural/low-SES transplant patients, limited FISH access, delayed intervention (donor lymphocyte infusion) leading to graft failure or relapse. Per cytogenetics practices aligned with ICMR and Indian Society of Blood and Marrow Transplantation guidelines, the test employs FISH for XX/XY chimerism over 1-2 days with high sensitivity/specificity, valuable for post-transplant surveillance in sex-mismatched cases. This diagnostic falls under post-transplant evaluation and targets recipients of opposite-sex BMT, addressing accurate detection to guide immunosuppression adjustment or relapse therapy. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise engraftment tracking and reducing transplant failure. Its whole blood-based approach ensures reliable sex chromosome detection.**Other Names**: FISH BMT Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: Sex-mismatched chimerism FISH; in India, used in transplant follow-up.**Purpose**: The test detects 2 parameters including XX/XY chimerism to guide transplant monitoring, assess donor cell engraftment, inform management.**Test Parameters**: 1. XX/XY Chimerism, 2. Donor Cell Detection.**Pretest Condition**: No fasting required; patients should be post opposite-sex BMT.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for FISH).**Medical History**: Patients should provide details on transplant date, donor sex, GVHD status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of poor engraftment including relapse, benefits of monitoring, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High donor XX/XY indicates engraftment; mixed/low suggests relapse risk, necessitating specialist input.**Specialist Consultation**: Transplant hematologists should be consulted for management.**Additional Supporting Tests**: STR PCR for confirmation.**Test Limitations**: Limited to sex-mismatched cases; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Transplant Studies India 2023. |
